Hanmi's New Story
Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi
Meet Us at ESMO Immuno-Oncology Congress 2025.
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumor
- Presentation Number
- 325TiP
- Session
- Poster Session, Dec. 11 at 16:15~18:00 PM, Room B
- Presenter
-
Seongjung Kim, Ph.D /
Hanmi Pharm Co., Ltd.
